门静脉血栓及肝动脉-门静脉瘘诊治再认识*

doi:10.3969/j.issn.1672-5069.2023.02.003

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (2): 160-163.doi: 10.3969/j.issn.1672-5069.2023.02.003

门静脉血栓及肝动脉-门静脉瘘诊治再认识^*

史海涛, 鲁晓岚

710004 西安市西安交通大学第二附属医院消化内科(史海涛);上海市复旦大学附属浦东医院消化内科(鲁晓岚)

收稿日期:2022-12-18 出版日期:2023-03-10 发布日期:2023-03-21
通讯作者: 鲁晓岚,E-mail:xiaolan_lu@163.com
作者简介:史海涛,男,38岁,医学博士,副主任医师。主要从事慢性肝病诊治研究。E-mail: shihaitao7@163.com
基金资助:
^*国家自然科学基金资助项目( 编号:82070587);浦东新区临床特色学科建设项目(编号:PWYts2021-11)

Portal vein thrombosis and hepatic arterio-portal fistula: a re-conceptualization of the diagnosis and treatment

Shi Haitao, Lu Xiaolan

Department of Gastroenterology, Second Affiliated Hospital, Jiaotong University, Xi’an 710004, Shaanxi Province, China

Received:2022-12-18 Online:2023-03-10 Published:2023-03-21

摘要/Abstract

关键词: 门静脉血栓, 肝动脉-门静脉瘘, 肝功能损害, 门静脉高压

Key words: Portal vein thrombosis, Hepatic arterio-portal fistula, Liver injury, Portal hypertension

史海涛, 鲁晓岚. 门静脉血栓及肝动脉-门静脉瘘诊治再认识^*[J]. 实用肝脏病杂志, 2023, 26(2): 160-163.

Shi Haitao, Lu Xiaolan. Portal vein thrombosis and hepatic arterio-portal fistula: a re-conceptualization of the diagnosis and treatment[J]. Journal of Practical Hepatology, 2023, 26(2): 160-163.

[1] Catherine NB, Arya R. Virchow and his triad: a question of attribution. Bri J Hematol, 2008, 143(2): 180-190.
[2] Anton A, Camprecios G, Perez-Campuzano V, et al. Thepathophysiology of portal vein thrombosis in cirrhosis: getting deeper into Virchow's triad. J Clin Med, 2022, 11(3): 800.
[3] Odriozola A, Puente Á, Cuadrado A, et al. Portal vein thrombosis in the setting of cirrhosis: A comprehensive review. J Clin Med, 2022, 11(21): 6435.
[4] Ju C, Li X, Gadani S, et al. Portal vein thrombosis: diagnosis and endovascular management. Rofo, 2022, 194(2): 169-180.
[5] Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells: implications for hypercoagulability in cirrhosis. J Hepatol, 2017, 67(5): 950-956.
[6] Kheyrandish S, Rastgar A, Arab-Zozani M, et al. Portal vein thrombosis might develop by COVID-19 infection or vaccination: a systematic review of case-report studies. Front Med (Lausanne), 2021, 8: 794599.
[7] Ogren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23, 796 consecutive autopsies. World J Gastroenterol, 2006, 12(13): 2115-2119.
[8] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海). 临床肝胆病杂志, 2020, 36(12): 2667-2674.
[9] Envelope RDFP, Bosch J, Garcia-Tsao G, e al. Baveno VII-renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[10] Dai J, Qi X, Li H, et al. Role ofD-dimer in the development of portal vein thrombosis in liver cirrhosis: a meta-analysis. Saudi J Gastroenterol, 2015, 21(3): 165-174.
[11] 张冬磊, 郝建宇, 杨宁. D-二聚体对肝硬化门静脉血栓形成的预测价值. 中华消化杂志, 2008, 28(10): 708-709.
[12] Wei Y, Chen X, Shen H, et al. P-selectin level at first and third day after portal hypertensive splenectomy for early prediction of portal vein thrombosis in patients with cirrhosis. Clin Appl Thromb Hemost, 2018, 24(suppl 9): 76s-83s.
[13] Buliarca A, Horhat A, Mocan T, et al. Viscoelastic tests in liver disease: where do we stand now? World J Gastroenterol, 2021, 27(23): 3290-3302.
[14] Fainchtein K, Tera Y, Kearn N, et al. Hypercoagulability and thrombosis risk in prostate cancer: the role of thromboelastography. Semin Thromb Hemost, 2022[ahead of print].
[15] Tarantino L, Ambrosino P, Minno M. Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol, 2015, 21(32): 9457-9460.
[16] Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis, 2017, 49(2): 113-120.
[17] Sofia C, Cattafi A, Silipigni S, et al. Portal vein thrombosis in patients with chronic liver diseases: from conventional to quantitative imaging. Eur J Radiol, 2021, 142: 109859.
[18] Lorenzo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology, 2017, 153(2): 480-487.
[19] Chun HS, Choe AR, Lee M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. Clin Mol Hepatol, 2021, 27(4): 535-552.
[20] Liu K, Li WD, Du XL, et al. Comparison of systemic thrombolysis versus indirect thrombolysis via the superior mesenteric artery in patients with acute portal vein thrombosis. Ann Vasc Surg, 2017, 39: 264-269.
[21] Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
[22] Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein. J Vasc Interv Radiol, 2005, 16(5): 651-661.
[23] Heaton ND, Davenport M, Karani J, et al. Congenital hepatoportal arteriovenous fistula. Surgery, 1995, 117(2): 170-174.
[24] Wu HY, Zhao W, Zhang JB, et al. Clinical characteristics of hepaticarterioportal shunts associated with hepatocellular carcinoma. BMC Gastroenterol, 2018, 18(1): 174.
[25] Guzman EA, McCahill LE, Rogers FB. Arterioportal fistulas: introduction of a novel classification with therapeutic implications. J Gastrointest Surg, 2006, 10(4): 543-550..
[26] Okuda K, Musha H, Yamasaki T, et al. Angiographic demonstration of intrahepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology, 1977, 122(1): 53-58.
[27] Zhang DY, Weng SQ, Dong L, et al. Portal hypertension induced by congenital hepatic arterioportal fistula: report of four clinical cases and review of the literature. World J Gastroenterol, 2015, 21(7): 2229-2235.
[28] Nakayama S. Intrahepatic arterioportal fistula. Intern Med, 2013, 52(20): 2371.
[29] Teplisky D, Tincani E, Lipsich J, et al. Congenital arterioportal fistulas: radiological treatment and color Doppler US follow-up. Pediatr Radiol, 2012, 42(11): 1326-1332.
[30] 陈志辉, 陈方红, 纪建松, 等. 超声造影对肝癌射频消融后继发性肝动脉-门静脉瘘的诊断价值. 医学影像学杂志, 2019, 29(2): 252-256.
[31] Sharpley J, Thode H, Sestina L, et al. Distal abdominal aortic thrombosis diagnosed by three-dimensional contrast-enhanced magnetic resonance angiography. Vet Radiol Ultrasound, 2009, 50(4): 370-375.
[32] Dumortier J, Pilleul F, Adham M, et al. Severe portal hypertension secondary to arterio-portal fistula: salvage surgical treatment. Liver Int, 2007, 27(6): 865-868.
[33] Saad WE, Davies MG, Rubens DJ, et al. Endoluminal management of arterioportal fistulae in liver transplant recipients: a single-center experience. Vasc Endovascular Surg, 2006, 40(6): 451-459.

门静脉血栓及肝动脉-门静脉瘘诊治再认识^*

Portal vein thrombosis and hepatic arterio-portal fistula: a re-conceptualization of the diagnosis and treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中华医学会肝病学分会中华医学会消化病学分会中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 实用肝脏病杂志, 2023, 26(2): 0-S4.
[2]	黄晓铨, 陈世耀. 重视规范化处理门静脉高压并发食管胃静脉曲张出血^*[J]. 实用肝脏病杂志, 2023, 26(1): 1-3.
[3]	赖瑞敏, 朱月永. 门静脉高压症:经颈静脉肝内门体分流术的合理应用及其相关并发症的预防和处理^*[J]. 实用肝脏病杂志, 2023, 26(1): 4-7.
[4]	许青, 杨健, 宗金娟. 特发性非肝硬化门静脉高压症患者肝脏影像学和病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 91-94.
[5]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[6]	李婷, 毛小荣, 张雪梅, 李俊峰. 脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 685-688.
[7]	陈靖, 朱月永. 无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？[J]. 实用肝脏病杂志, 2022, 25(1): 9-12.
[8]	赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展[J]. 实用肝脏病杂志, 2021, 24(5): 613-616.
[9]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究[J]. 实用肝脏病杂志, 2021, 24(3): 419-422.
[10]	吴荣刚, 张必全, 王珍. CT相关参数判断乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血风险的价值研究[J]. 实用肝脏病杂志, 2020, 23(6): 853-856.
[11]	宋丽俊, 袁雁, 王伟. 定量磁共振成像诊断原发性胆汁性肝硬化患者门静脉高压症价值分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 568-571.
[12]	热那特·克力木,吐尔干艾力·阿吉,邵英梅. 肝硬化并发门静脉血栓患者临床特征及其危险因素分析[J]. 实用肝脏病杂志, 2020, 23(3): 401-404.
[13]	韩东,彭经纬,谢辉晋. 脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究[J]. 实用肝脏病杂志, 2020, 23(3): 409-412.
[14]	陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.
[15]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.